Turn Therapeutics Inc Dossier - Source-backed chat

Turn Therapeutics Inc

TTRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.53

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $14.39Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $437M

Enterprise Value $433.1M

Shares Outstanding 30.1M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Turn Therapeutics Inc. (NASDAQ: TTRX) is a clinical-stage dermatology and immunology company positioned for a major near-term valuation inflection. The company's proprietary PermaFusion platform enables the stable suspension of active ingredients in oil-based carriers without emulsifiers, enhancing bioavailability and safety. Its lead asset, GX-03 (a topical IL-36/IL-31 pathway inhibitor), recently demonstrated highly encouraging Phase 2 interim results in moderate-to-severe atopic dermatitis, showing rapid onset and strong efficacy (92.6% EASI-50 at 4 weeks vs. 65.2% for vehicle) with an excellent safety profile. Backed by a newly secured $25 million growth capital facility from Avenue Capital and a commercial partnership with Medline expected to generate near-term revenue in late 2026, Turn Therapeutics offers a highly asymmetric risk-reward profile ahead of its mid-2026 Phase 2 topline readout.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$26.00

Mean target$26.00

High · most bullish analyst$26.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5015%

The bear case assumes that the final Phase 2 topline data shows a significant drop in efficacy or unexpected safety/tolerability issues when evaluated across the full patient cohort, narrowing the therapeutic window. FDA interactions result in a demanding and costly Phase 3 trial design, requiring the company to raise substantial dilutive capital. Medline commercial launch is delayed into 2027, extending the cash burn and depressing the stock toward its 52-week low.

Base CaseCentral scenario

$8.0065%

The base case assumes that the upcoming Phase 2 topline data for GX-03 in moderate-to-severe atopic dermatitis confirms the strong efficacy and safety trends observed in the interim analysis. The company successfully aligns with the FDA on a Phase 3 design emphasizing Week 4 endpoints (such as EASI-75). Medline commercialization begins in late 2026, providing non-dilutive cash flow. The stock moves toward the consensus analyst price target of $8.00 as clinical de-risking attracts institutional interest.

Bull CaseUpside scenario

$12.0025%

The bull case assumes that the Phase 2 topline data for GX-03 in atopic dermatitis demonstrates exceptional efficacy (e.g., EASI-75 exceeding 75% at Week 4) and a pristine safety profile, positioning it as a clear first-line non-steroidal topical therapy. The FDA grants an expedited review path or breakthrough designation, accelerating the Phase 3 timeline. Concurrently, the Medline partnership launches ahead of schedule in late 2026, generating substantial upfront and milestone revenues that fully fund the pipeline through commercialization without dilution.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase 2 interim data for lead asset GX-03, showing rapid onset of action and 92.6% EASI-50 responder rate at Week 4.
Proprietary PermaFusion platform technology validated by multiple FDA-cleared medical devices, reducing formulation risk.
Secured up to $25 million growth capital facility from Avenue Capital, extending cash runway into late 2027.
Commercial partnership with Medline (the largest US provider of medical-surgical products) poised to generate near-term revenue in late 2026.
Highly experienced leadership and advisory team, including former FDA Commissioner Dr. Stephen Hahn overseeing clinical and regulatory strategy.

Key Investment Risks

Clinical trial risk: Lead candidate GX-03 must still successfully complete Phase 2 and undergo large-scale Phase 3 trials.
Financial risk: The company is currently unprofitable and pre-revenue, relying on debt facilities and capital markets to fund R&D.
Regulatory risk: Evolving FDA requirements for topical immunomodulators could delay clinical timelines or increase Phase 3 costs.
Commercial execution risk: Future revenue is highly dependent on the successful launch and marketing of products by partner Medline.

Thesis Invalidation Triggers

Phase 2 topline data fails to show statistically significant separation from vehicle on primary or key secondary endpoints.
Emergence of serious treatment-related adverse events or tolerability issues in the final Phase 2 cohort.
FDA requires an unexpectedly large or long Phase 3 program that exceeds the company's current capital resources.
Termination or material delay of the global supply and license agreement with Medline.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.